117 related articles for article (PubMed ID: 17198519)
1. Is the current anti-osteoporotic therapy paradigm good enough?
Fisher AA; Davis MW
J Am Geriatr Soc; 2006 Dec; 54(12):1960-1, author reply 1961-3. PubMed ID: 17198519
[No Abstract] [Full Text] [Related]
2. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.
Liu H; Michaud K; Nayak S; Karpf DB; Owens DK; Garber AM
Arch Intern Med; 2006 Jun; 166(11):1209-17. PubMed ID: 16772249
[TBL] [Abstract][Full Text] [Related]
3. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
Babb RR
N Engl J Med; 2008 Mar; 358(12):1302-3; author reply 1303-4. PubMed ID: 18357641
[No Abstract] [Full Text] [Related]
4. [Cost effective osteoporosis therapy. Alendronate is also immediately available as a generic drug].
MMW Fortschr Med; 2005 Dec; 147(49-50):74-5. PubMed ID: 16401016
[No Abstract] [Full Text] [Related]
5. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
Rossi CM; Di Comite G
N Engl J Med; 2008 Mar; 358(12):1302; author reply 1303-4. PubMed ID: 18354112
[No Abstract] [Full Text] [Related]
6. Cost effectiveness of teriparatide and PTH(1-84) in the treatment of postmenopausal osteoporosis.
Borgström F; Ström O; Marin F; Kutahov A; Ljunggren O
J Med Econ; 2010; 13(3):381-92. PubMed ID: 20604678
[TBL] [Abstract][Full Text] [Related]
7. [Teriparatide: an anabolic drug for the treatment of patients with osteoporosis].
Toenders WG
Ned Tijdschr Geneeskd; 2006 Apr; 150(15):879; author reply 879. PubMed ID: 16676521
[No Abstract] [Full Text] [Related]
8. Anabolic therapy in glucocorticoid-induced osteoporosis.
Sambrook PN
N Engl J Med; 2007 Nov; 357(20):2084-6. PubMed ID: 18003966
[No Abstract] [Full Text] [Related]
9. [Treatment with recombinant parathyroid hormone of advanced osteoporosis--series of cases].
Skiba K; Adamczak M; Wiecek A
Przegl Lek; 2011; 68(7):391-5. PubMed ID: 22010479
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of early bone histomorphometric effects of parathormone and alendronate in osteoporotic women].
Arlot M; Roux JP; Portero N; Boivin G; Meunier PJ
Rev Med Suisse Romande; 2004 Feb; 124(2):91-2. PubMed ID: 15095621
[TBL] [Abstract][Full Text] [Related]
11. Commentary on Mobley and Others: importance of assumptions about VTE mortality in modeling the cost-effectiveness of osteoporosis therapies.
Meadows ES; Stock J; Johnston JA
Med Decis Making; 2006; 26(6):633-5; author reply 636-7. PubMed ID: 17099202
[No Abstract] [Full Text] [Related]
12. The teriparatide in the treatment of severe senile osteoporosis.
Manuele S; Sorbello L; Puglisi N; Grasso S; La Malfa L; D'Urbino G; Rizzotto M; Strano S; Maugeri D
Arch Gerontol Geriatr; 2007; 44 Suppl 1():249-58. PubMed ID: 17317460
[TBL] [Abstract][Full Text] [Related]
13. [Using parathyroid hormone 1-84 in the treatment of osteoporosis: presentation and comments of main clinical trial].
Cesareo R; Napolitano C; Iozzino M; Romitelli F; Iarussi G; Scona M; De Rosa B
Clin Ter; 2009; 160(4):307-10. PubMed ID: 19795085
[TBL] [Abstract][Full Text] [Related]
14. Are there any alternatives to alendronate (Fosamax) for osteoporosis to avoid the risk of osteonecrosis of the jaw?
Wynn RL
Gen Dent; 2007; 55(6):495-8. PubMed ID: 18050572
[No Abstract] [Full Text] [Related]
15. By the way, doctor. I'm 60 and have osteoporosis. My doctor is recommending Fosamax, but I'm concerned about jawbone problems. Are there any other drugs I can take?
Robb-Nicholson C
Harv Womens Health Watch; 2006 Dec; 14(4):8. PubMed ID: 17299880
[No Abstract] [Full Text] [Related]
16. [Parathyroid and bone. Role of parathyroid hormone in the treatment of osteoporosis].
Nakamura T
Clin Calcium; 2007 Dec; 17(12):1823-9. PubMed ID: 18057656
[TBL] [Abstract][Full Text] [Related]
17. Bone densitometry and treatment for osteoporosis in older men.
Ito K
JAMA; 2007 Nov; 298(18):2136-7; author reply 2137. PubMed ID: 18000194
[No Abstract] [Full Text] [Related]
18. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
Adachi JD; Hanley DA; Lorraine JK; Yu M
Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
Inderjeeth CA; Foo AC; Lai MM; Glendenning P
Bone; 2009 May; 44(5):744-51. PubMed ID: 19130909
[TBL] [Abstract][Full Text] [Related]
20. [Parathyroid and bone. Evidence and perspective of parathyroid therapy for patients with osteoporosis].
Wada S; Fukawa T; Kamiya S
Clin Calcium; 2007 Dec; 17(12):1888-94. PubMed ID: 18057665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
